美股市場個股詳情

AMLX Amylyx Pharmaceuticals

添加自選

1.840
+0.010+0.55%

交易中 05/17 15:16 (美東)

1.25億總市值-1719市盈率TTM

Amylyx Pharmaceuticals股票討論區

登錄發表評論

Amar Amin

04/27 07:58

$Amylyx Pharmaceuticals(AMLX.US)$ flat and searching for the new low. How much lower can it be 😂

Rooster77

04/17 01:13

$Amylyx Pharmaceuticals(AMLX.US)$ flat

Trytosaveabit

04/10 21:07

Update

$Amylyx Pharmaceuticals(AMLX.US)$ Amylyx Pharmaceuticals Announces Interim Data From Phase 2 HELIOS Clinical Trial Of AMX0035 In Adults With Wolfram Syndrome
Benzinga· 4 mins ago
Interim analysis, including eight participants assessed at Week 24, demonstrated improvements in pancreatic function and glycemic control, as measured by C-peptide and other markers of glucose metabolism, rather than worsening typically expected with disease progression
- All eight participants met prespecified r...

Jaguar8

04/10 21:02

$Amylyx Pharmaceuticals(AMLX.US)$
NEWS
Amylyx Pharmaceuticals Announces Interim Data From Ongoing Phase 2 HELIOS Clinical Trial Demonstrating Improvements in Pancreatic Function and Glycemic Control with AMX0035 in People with Wolfram Syndrome
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) announced positive interim data from the Phase 2 HELIOS clinical trial of AMX0035 in adults with Wolfram syndrome. The data showed improvements in pancreatic function, glycemic control, and vision, with all parti...

Moomoo AI

04/06 22:07

Analysts predict a revenue drop and higher losses per share for Amylyx Pharmaceuticals, indicating slower sales growth than the market, potentially causing market wariness.

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Analysts Are More Bearish Than They Used To Be

Trytosaveabit

04/04 19:20

But some good now! Hehehe

$Amylyx Pharmaceuticals(AMLX.US)$ Amylyx Pharmaceuticals To Advance AMX0035 In Wolfram Syndrome And Progressive Supranuclear Palsy, And AMX0114 In Amyotrophic Lateral Sclerosis, Interim Data From Phase 2 Helios Trial Of AMX0035 For Wolfram Syndrome Are Expected In April 2024

Trytosaveabit

04/04 19:18

A bit more

$Amylyx Pharmaceuticals(AMLX.US)$ Amylyx Pharmaceuticals Will Reduce Its Workforce By Approximately 70% To Focus Resources On Key Clinical And Preclinical Programs And Extends Expected Cash Runway Into 2026

Trytosaveabit

04/04 19:18

Update! Hmm? Grrr!

$Amylyx Pharmaceuticals(AMLX.US)$ Amylyx Pharmaceuticals Announces Formal Intention to Remove Relyvrio/Albrioza From The Market
Moomoo 24/7· 1 min ago
Relyvrio/Albrioza will no longer be available for new patients as of today; Patients currently on therapy in the U.S. and Canada who, in consultation with their physician, wish to continue can be transitioned to a free drug program; PHOENIX Open Label Extension is ongoing